ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1877

Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics

Yiming Luo1, Kaitlin Quinn2, Marcela Ferrada1, Elaine Novakovich1 and Peter Grayson3, 1National Institutes of Health, Bethesda, MD, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: Infection, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Takayasu’s arteritis (TAK) is an idiopathic inflammatory disease primarily affecting the aorta and its major branches. Mycobacterium tuberculosis is prevalent in developing countries and can cause latent or active tuberculosis (TB) of the lung or other organs. Increased prevalence of TB has been reported in TAK but a causal relationship has not been established. The study objective was to determine if clinical characteristics differ among patients with TAK with known TB exposure.

Methods: Patients with TAK were recruited to a prospective observational cohort. All patients fulfilled the 1990 ACR Classification Criteria for TAK. TB was identified by medical history and/or Quantiferon-Gold screening. Categorical and continuous variables were compared using the Fisher’s exact test and Mann-Whitney test, respectively. Vascular calcification was based on radiology report of high-density lesions consistent with calcium deposition in large- or medium-size arterial territories on CT scans. Relapse was defined as clinical assessment showing recurrence of active vasculitis requiring escalation of immunosuppressive therapy after a period of stable remission. Incidentally found was defined as receiving diagnostic work up for non-TAK non-TB related indications which leads to unexpected discovery of vascular pathology. Asymptomatic was defined as complete absence of any vascular or systemic symptoms.

Results: Among 80 patients with TAK, 10 patients had a history of TB. 8 patients had latent TB, 1 patient had TB endometritis, and 1 patient had TB lymphadenitis and erythema induratum. All patients with active TB completed anti-active TB treatment. 7 of out 8 patients with latent TB completed anti-latent treatment and 1 patent with latent TB was recommended to start treatment. The majority of the patients were female (9 (90%) in TB-TAK and 61 (87%) in non-TB TAK). Compared to those without TB, TAK patients with TB were older at diagnosis (35 vs 26 years, p = 0.03) and less likely to be Caucasian (9 (10%) vs 51 (73%), p = 0.002). TAK patients with TB had longer disease duration (17 vs 9 years, p = 0.03), were more likely to be asymptomatic at diagnosis (2 (20%) vs 1 (1%), p = 0.001) or diagnosed based on incidentally found vascular pathology (50% vs 6%, p = 0.005). Patients with TB-TAK had distinct patterns of vascular disease, including increased thoracic aorta involvement (80% vs 40%, p = 0.037), aortic aneurysms (5 (50%) vs 4 (16%), p = 0.01), and vascular calcification (4 (40%) vs 9 (13%), p = 0.05). In terms of treatment, patients with TAK-TB were less likely to have ever received treatment with glucocorticoids (5 (50%) vs 64 (91%), p = 0.003), DMARDs (6 (60%) vs 65 (93%), p = 0.012), or biologics (2 (20%) vs 43 (61%), p = 0.018). Despite receiving less treatment, relapse was less frequent in patients with TB-TAK (3 (30%) vs 45 (66%), p = 0.039).

Conclusion: Patient with TAK and TB have unique clinical characteristics. Compared to other patients, patients with TAK and TB are more likely to have clinically indolent disease, have more structural damage to the aorta, receive less treatment, and are less likely to experience relapse. These data provide preliminary evidence in support of a potential causal relationship between TAK and TB.


Disclosures: Y. Luo, None; K. Quinn, None; M. Ferrada, None; E. Novakovich, None; P. Grayson, None.

To cite this abstract in AMA style:

Luo Y, Quinn K, Ferrada M, Novakovich E, Grayson P. Takayasu Arteritis Patients with Tuberculosis Have Unique Clinical Characteristics [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/takayasu-arteritis-patients-with-tuberculosis-have-unique-clinical-characteristics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/takayasu-arteritis-patients-with-tuberculosis-have-unique-clinical-characteristics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology